The Experts below are selected from a list of 282 Experts worldwide ranked by ideXlab platform
Harry W. Herr - One of the best experts on this subject based on the ideXlab platform.
-
can restaging Transurethral Resection of t1 bladder cancer select patients for immediate cystectomy
The Journal of Urology, 2007Co-Authors: Harry W. Herr, Machele S Donat, Guido DalbagniAbstract:Purpose: We determined whether pathological findings on restaging Transurethral Resection predict early stage progression of T1 bladder cancer.Materials and Methods: A cohort of 352 patients presenting with T1 bladder cancer on initial Transurethral Resection was evaluated by second or restaging Transurethral Resection. All patients received bacillus Calmette-Guerin therapy and 88% were followed for 5 years. Pathological findings on restaging Transurethral Resection were correlated with tumor features, stage progression frequency and progression-free survival.Results: Of the 352 patients with T1 tumors 203 (58%) had residual tumor on restaging Transurethral Resection, including 92 (26%) with residual nonmuscle invasive (T1) cancer. During 5 years 66% of cases recurred and 35% progressed in stage. Of the 92 patients with residual T1 cancer 75 (82%) progressed to muscle invasion within 5 years compared to 49 of 260 (19%) who had no or nonT1 tumor detected on restaging Transurethral Resection.Conclusions: Re...
-
the value of a second Transurethral Resection in evaluating patients with bladder tumors
The Journal of Urology, 2000Co-Authors: Harry W. HerrAbstract:AbstractPurpose: The role of a routine second Transurethral Resection in evaluating and managing bladder tumors is defined.Materials and Methods: From January to October 1998, 150 patients with new or recurrent bladder tumors underwent repeat Transurethral Resection within 2 to 6 weeks after the initial Resection, and the results, including the presence of residual tumor and tumor stage, were compared.Results: Of the 150 cases 36 (24%) had no and 114 (76%) had residual tumor on repeat Transurethral Resection. Of 96 cases with superficial (Ta, Tis, T1) bladder tumors 72 (75%) had residual noninvasive tumor and 28 (29%) were up staged to invasive tumor. Among 54 patients with a muscle invasive tumor 12 (22%) had no residual tumor on repeat Transurethral Resection. Results of the second Resection changed tumor treatment in 50 patients (33%).Conclusions: Many patients with bladder tumors have tumor present after an initial Transurethral Resection. Routine repeat Resection is advised to control noninvasive tum...
-
Transurethral Resection in regionally advanced bladder cancer.
The Urologic clinics of North America, 1992Co-Authors: Harry W. HerrAbstract:Various treatments have proved useful for disease control in some patients with regionally advanced bladder cancer. Transurethral Resection may cure some patients with invasive disease, but identifying patients with such potential early in their course is difficult. A restaging Transurethral Resection helps indicate whether conservative management is feasible and, if not, which operation is appropriate. In some patients, Transurethral Resection may enhance the response to chemotherapy. Research is needed to identify those tumor characteristics associated with good results of conservative management of regionally advanced bladder cancer.
William A. See - One of the best experts on this subject based on the ideXlab platform.
-
Can restaging Transurethral Resection of T1 bladder cancer select patients for immediate cystectomy
Urologic Oncology: Seminars and Original Investigations, 2007Co-Authors: William A. SeeAbstract:Purpose We determined whether pathological findings on restaging Transurethral Resection predict early stage progression of T1 bladder cancer. Materials and Methods A cohort of 352 patients presenting with T1 bladder cancer on initial Transurethral Resection was evaluated by second- or restaging Transurethral Resection. All patients received bacillus Calmette-Guerin therapy and 88% were followed for 5 years. Pathological findings on restaging Transurethral Resection were correlated with tumor features, stage progression frequency, and progression-free survival. Results Of the 352 patients with T1 tumors, 203 (58%) had residual tumor on restaging Transurethral Resection, including 92 (26%) with residual nonmuscle invasive (T1) cancer. During 5 years, 66% of cases recurred and 35% progressed in stage. Of the 92 patients with residual T1 cancer, 75 (82%) progressed to muscle invasion within 5 years compared with 49 of 260 (19%) who had no or non-T1 tumor detected on restaging Transurethral Resection. Conclusions Restaging Transurethral Resection identifies patients with T1 bladder cancer who are at high risk for early tumor progression, justifying immediate cystectomy.
Zhang Hong-shuan - One of the best experts on this subject based on the ideXlab platform.
-
Second Transurethral Resection for Superficial Bladder Cancer
Chinese Journal of General Practice, 2011Co-Authors: Zhang Hong-shuanAbstract:Objective To evaluate the potential benefit of a second Transurethral Resectionfor the superficial bladder cancer.Methods A second Transurethral Resection was performed in 39 patients with newly diagnosed superficial bladder cancer since 2005 in our department.All the patients had immediate intravesical treatment with 20 mg Mitomycin after initial TURBt.Then all of them had weekly the same treatment until 4 weeks after the first TUR operation.The second Transurethral Resection was performed after 4 weeks of the first Transurethral Resection.The surgical sites from the second Resection included original surgical area plus 1cm margin.We also had biopsies at the baseline and suspected bladder mucosa.We reviewed all the pathological findings.Results Of the 39 patients who underwent second Transurethral Resection,5 cases(12.8%) had residual cancer.2 of 5 patients had a higher stage after the second Transurethral Resection.50% of G3 tumors had a positive second Transurethral Resection.Also,there were more likely higher positive findings of T1 tumors in second Transurethral Resection.Conclusion Although second Transurethral Resection dramatically changed the treatment strategy in a small percentage of cases,we strongly recommend performing second Transurethral Resection in high risk superficial bladder cancer,especially in G3 tumors.
Guido Dalbagni - One of the best experts on this subject based on the ideXlab platform.
-
can restaging Transurethral Resection of t1 bladder cancer select patients for immediate cystectomy
The Journal of Urology, 2007Co-Authors: Harry W. Herr, Machele S Donat, Guido DalbagniAbstract:Purpose: We determined whether pathological findings on restaging Transurethral Resection predict early stage progression of T1 bladder cancer.Materials and Methods: A cohort of 352 patients presenting with T1 bladder cancer on initial Transurethral Resection was evaluated by second or restaging Transurethral Resection. All patients received bacillus Calmette-Guerin therapy and 88% were followed for 5 years. Pathological findings on restaging Transurethral Resection were correlated with tumor features, stage progression frequency and progression-free survival.Results: Of the 352 patients with T1 tumors 203 (58%) had residual tumor on restaging Transurethral Resection, including 92 (26%) with residual nonmuscle invasive (T1) cancer. During 5 years 66% of cases recurred and 35% progressed in stage. Of the 92 patients with residual T1 cancer 75 (82%) progressed to muscle invasion within 5 years compared to 49 of 260 (19%) who had no or nonT1 tumor detected on restaging Transurethral Resection.Conclusions: Re...
Jean De La Rosette - One of the best experts on this subject based on the ideXlab platform.
-
Bipolar Transurethral Resection of the prostate: the 'golden standard' reclaims its leading position.
Current opinion in urology, 2009Co-Authors: Charalampos Mamoulakis, Marleen Trompetter, Jean De La RosetteAbstract:To summarize recent knowledge from experimental studies and randomized clinical trials in benign prostate hyperplasia that compare bipolar with monopolar Transurethral Resection, with an emphasis on morbidity. Bipolar Transurethral Resection of the prostate has a urodynamically proven efficacy to relieve bladder outlet obstruction, which seems to be durable in time with low long-term complication rates. The haemostatic capacity of bipolar current is shown to be superior in ex-vivo studies. Postoperative bleeding and blood transfusion rates are similar. Clot retention and Transurethral Resection syndrome rates are significantly lower in patients treated with bipolar Resection. Catheterization time and length of hospital stay are statistically shorter for Gyrus but insignificant for the Transurethral Resection in a saline system compared with monopolar Resection. Urethral stricture rates do not differ significantly between arms. Bipolar shares similar clinical efficacy with monopolar Transurethral Resection of the prostate, durable in time with low long-term complication rates. It has minimized bleeding risk and eliminated Transurethral Resection syndrome. The evidence derived from randomized clinical trials does not support a statistically significant incidence of urethral strictures with bipolar compared with monopolar current.
-
Bipolar Transurethral Resection of the prostate: the 'golden standard' reclaims its leading position.
Current Opinion in Urology, 2009Co-Authors: Charalampos Mamoulakis, Marleen Trompetter, Jean De La RosetteAbstract:Purpose of reviewTo summarize recent knowledge from experimental studies and randomized clinical trials in benign prostate hyperplasia that compare bipolar with monopolar Transurethral Resection, with an emphasis on morbidity.Recent findingsBipolar Transurethral Resection of the prostate has a urody
